Biogen Inc. Common Stock (BIIB) Stock Price

BIIBStock

$220.77+56.57%52W

Market Cap$32.62B

P/E24.01x

PEG Ratio1.53

Div yield—

Beta0.09

BIIB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)1.11%

Price vs S&P 500 (4W)3.03%

PEG Ratio1.53

VGM Score49.65

P/E Ratio (Annual)24.01x

P/CF (Annual)14.08x

Book Value / Share (Quarterly)$127.61

P/TBV (Annual)2.84x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-0.93%

Cash Flow / Share (Quarterly)$17.20

Price vs S&P 500 (YTD)11.98%

Gross Margin (TTM)73.99%

Net Profit Margin (TTM)8.32%

EPS (TTM)$5.65

10-Day Avg Trading Volume0.75M

EPS Excl Extra (TTM)$5.65

Revenue Growth (5Y)-5.96%

EPS (Annual)$8.79

ROI (Annual)5.27%

Gross Margin (Annual)75.99%

Net Profit Margin (5Y Avg)17.17%

Cash / Share (Quarterly)$8.70

P/E Basic Excl Extra (TTM)37.20x

Revenue Growth QoQ (YoY)3.42%

EPS Growth (5Y)-18.77%

P/E Normalized (Annual)24.01x

ROA (Last FY)4.39%

Revenue Growth TTM (YoY)0.31%

EBITD / Share (TTM)$11.28

ROE (5Y Avg)12.34%

Operating Margin (TTM)10.91%

Cash Flow / Share (Annual)$13.76

P/B Ratio1.65x

P/B Ratio (Quarterly)1.69x

Net Income / Employee (Annual)$172,400

EV / Revenue (TTM)3.77x

Net Interest Coverage (TTM)4.24x

ROA (TTM)2.78%

EPS Growth QoQ (YoY)-84.85%

EV / EBITDA (TTM)22.71x

EPS Incl Extra (Annual)$8.79

Current Ratio (Annual)2.68x

Quick Ratio (Quarterly)1.26x

3-Month Avg Trading Volume1.17M

52-Week Price Return56.57%

EV / Free Cash Flow (Annual)18.75x

P/E Incl Extra (TTM)37.20x

Revenue / Employee (TTM)$1,337,100

Tangible BV / Share (Quarterly)$35.66

P/S Ratio (Annual)3.14x

Asset Turnover (Annual)0.34x

52-Week High$222.15

Operating Margin (5Y Avg)24.59%

EPS Excl Extra (Annual)$8.79

CapEx CAGR (5Y)-19.60%

Tangible BV CAGR (5Y)3.58%

26-Week Price Return12.36%

Quick Ratio (Annual)1.82x

13-Week Price Return15.12%

Total Debt / Equity (Annual)0.34x

Current Ratio (Quarterly)1.87x

Enterprise Value$37.85B

Revenue / Share Growth (5Y)-4.24%

Asset Turnover (TTM)0.33x

Book Value / Share Growth (5Y)12.07%

Revenue / Employee (Annual)$1,318,700

Inventory Turnover (Annual)1.03x

Pretax Margin (Annual)15.74%

Cash / Share (Annual)$26.01

3-Month Return Std Dev39.00%

Gross Margin (5Y Avg)77.42%

Net Income / Employee (TTM)$111,300

EBITDA CAGR (5Y)-14.23%

EBITDA Interim CAGR (5Y)-10.24%

ROE (Last FY)7.08%

Net Interest Coverage (Annual)3.45x

EPS Basic Excl Extra (Annual)$8.79

P/FCF (TTM)12.22x

Receivables Turnover (TTM)4.47x

EV / Free Cash Flow (TTM)14.90x

Total Debt / Equity (Quarterly)0.43x

EPS Incl Extra (TTM)$5.65

Receivables Turnover (Annual)5.29x

ROI (TTM)3.31%

P/S Ratio (TTM)3.10x

Pretax Margin (5Y Avg)19.96%

Revenue / Share (Annual)$67.24

Tangible BV / Share (Annual)$61.88

Forward P/E14.02x

Free OCF CAGR (5Y)-11.30%

Price vs S&P 500 (52W)38.26%

P/E Ratio (TTM)37.20x

EPS Growth TTM (YoY)-46.02%

Year-to-Date Return23.94%

5-Day Price Return2.62%

EPS Normalized (Annual)$8.79

ROA (5Y Avg)6.69%

Net Profit Margin (Annual)13.07%

Month-to-Date Return7.47%

Cash Flow / Share (TTM)$13.34

EBITD / Share (Annual)$15.16

EPS Growth (3Y)-25.04%

Operating Margin (Annual)17.42%

LT Debt / Equity (Annual)0.34x

P/CF (TTM)10.78x

ROI (5Y Avg)8.35%

P/E Excl Extra (TTM)37.20x

LT Debt / Equity (Quarterly)0.39x

EPS Basic Excl Extra (TTM)$5.65

P/TBV (Quarterly)6.06x

P/B Ratio (Annual)1.41x

Inventory Turnover (TTM)1.12x

Pretax Margin (TTM)10.09%

Book Value / Share (Annual)$124.45

Price vs S&P 500 (13W)12.33%

Net Margin Growth (5Y)-15.17%

Beta0.09x

P/FCF (Annual)15.38x

Revenue / Share (TTM)$67.44

ROE (TTM)4.51%

52-Week Low$131.52

vGradeC

gGradeD

mGradeB

vgmGradeC

BIIB Earnings Surprise History

Q2 255.47est. 3.88

Q3 254.81est. 3.88

Q4 251.99est. 1.62

Q1 263.57est. 2.89

Q2 263.60est. 2.03

BIIB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.74

3.80

3.82

3.86

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Biogen Inc. Common Stock

Biogen is a biopharmaceutical company focused on neurodegenerative and rare diseases. Its revenue base is anchored by multiple sclerosis therapies (40% of 2025 revenue) and a CD20 collaboration with Roche (19%), though the MS franchise is declining. The company is diversifying through emerging treatments including Leqembi for Alzheimer's disease, Spinraza for spinal muscular atrophy, and programs addressing postpartum depression, Friedreich's ataxia, and amyotrophic lateral sclerosis.